Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program

book icon

Publication Details

location-icon

Circulation: Genomic and Precision Medicine

calander-icon

August 2021

Access Here 
pen icon

Author(s)

Barry H Trachtenberg1, Sachin K Shah2, Robert L Nussbaum3, Sara L Bristow3, Ruthvik Malladi2, Matteo Vatta3

Affiliations

Affiliations

1Methodist DeBakey Heart and Vascular Center, Houston, TX (B.H.T.); 2Alnylam Pharmaceuticals, Cambridge, MA (S.K.S., R.M.); 3Invitae, San Francisco, CA (R.L.N., S.L.B., M.V.)

abstract

PMID

34461735

abstract

DOI

10.1161/circgen.121.003466

book

Publication Materials

wip-bg

Visit website/URL/link

Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program

Presentation
menuscript Manuscript

Related Materials

Transthyretin Amyloidosis (ATTR)

Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy

European Journal of Heart Failure

Author(s)

Pablo Garcia-Pavia, Martha Grogan, Parag Kale, et al

February 2024

Transthyretin Amyloidosis (ATTR)

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis

New England Journal of Medicine

Author(s)

Mathew Maurer, Parag Kale, Marianna Fontana, et al

October 2023

Transthyretin Amyloidosis (ATTR)

Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation

Clinical Pharmacokinetics

Author(s)

Prajakta Badri, Bahru Habtemariam, Megan Melch, et al

August 2023

Transthyretin Amyloidosis (ATTR)

Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study

Amyloid

Author(s)

Simina Ticau, Emre Aldinc, Michael Polydefkis, et al

July 2023

Transthyretin Amyloidosis (ATTR)

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Neurology and Therapy

Author(s)

Laura Obici, Senda Ajroud-Driss, Kon-Ping Lin, et al

July 2023

Transthyretin Amyloidosis (ATTR)

Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy

Expert Opinion on Pharmacotherapy

Author(s)

Madeline Merkel, David Danese, Chongshu Chen, et al

May 2023